Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
Vor Bio (Nasdaq: VOR) has appointed Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025. Mahatme brings over 30 years of executive leadership experience in the biopharmaceutical industry, most recently serving as President, COO, and CFO of National Resilience, where he raised over $2.5 billion in capital.
At his previous role at Sarepta Therapeutics, Mahatme led capital formation efforts exceeding $3.5 billion and expanded the company's pipeline through strategic initiatives. The appointment comes as Vor Bio advances telitacicept through global Phase 3 development for generalized myasthenia gravis, with the drug already approved in China for multiple autoimmune indications.
Vor Bio (Nasdaq: VOR) ha nominato Sandy Mahatme come Chief Financial Officer e Chief Business Officer, con decorrenza dal 9 luglio 2025. Mahatme vanta oltre 30 anni di esperienza dirigenziale nel settore biofarmaceutico, avendo ricoperto recentemente i ruoli di Presidente, COO e CFO di National Resilience, dove ha raccolto più di 2,5 miliardi di dollari di capitale.
Nel suo precedente incarico presso Sarepta Therapeutics, Mahatme ha guidato operazioni di raccolta fondi per oltre 3,5 miliardi di dollari e ha ampliato il portafoglio prodotti dell'azienda tramite iniziative strategiche. La nomina arriva mentre Vor Bio sta portando avanti lo sviluppo globale di fase 3 di telitacicept per la miastenia gravis generalizzata, con il farmaco già approvato in Cina per diverse indicazioni autoimmuni.
Vor Bio (Nasdaq: VOR) ha nombrado a Sandy Mahatme como Director Financiero y Director Comercial, con efecto a partir del 9 de julio de 2025. Mahatme aporta más de 30 años de experiencia en liderazgo ejecutivo en la industria biofarmacéutica, habiendo desempeñado recientemente los cargos de Presidente, COO y CFO en National Resilience, donde recaudó más de 2.500 millones de dólares en capital.
En su rol anterior en Sarepta Therapeutics, Mahatme lideró esfuerzos de formación de capital que superaron los 3.500 millones de dólares y amplió la cartera de la empresa mediante iniciativas estratégicas. El nombramiento se produce mientras Vor Bio avanza con el desarrollo global de fase 3 de telitacicept para la miastenia gravis generalizada, con el medicamento ya aprobado en China para múltiples indicaciones autoinmunes.
Vor Bio (나스닥: VOR)는 2025년 7월 9일부로 Sandy Mahatme를 최고재무책임자(CFO) 겸 최고사업책임자(CBO)로 임명했습니다. Mahatme는 생명공학 제약 산업에서 30년 이상의 경영 리더십 경험을 보유하고 있으며, 최근에는 National Resilience에서 사장, COO, CFO로 재직하며 25억 달러 이상의 자본을 조달한 바 있습니다.
이전 직장인 Sarepta Therapeutics에서는 35억 달러가 넘는 자본 조달을 이끌었고, 전략적 이니셔티브를 통해 회사의 파이프라인을 확장했습니다. 이번 임명은 Vor Bio가 전신성 중증근무력증 치료제인 텔리타시셉트의 글로벌 3상 개발을 진행 중인 가운데 이루어졌으며, 이 약물은 이미 중국에서 여러 자가면역 질환 적응증으로 승인받았습니다.
Vor Bio (Nasdaq : VOR) a nommé Sandy Mahatme au poste de Directeur Financier et Directeur des Affaires, à compter du 9 juillet 2025. Mahatme apporte plus de 30 ans d'expérience en leadership exécutif dans l'industrie biopharmaceutique, ayant récemment occupé les fonctions de Président, COO et CFO chez National Resilience, où il a levé plus de 2,5 milliards de dollars de capitaux.
Dans son précédent poste chez Sarepta Therapeutics, Mahatme a mené des levées de fonds dépassant 3,5 milliards de dollars et a élargi le pipeline de l'entreprise grâce à des initiatives stratégiques. Cette nomination intervient alors que Vor Bio fait progresser le développement mondial de phase 3 de telitacicept pour la myasthénie généralisée, le médicament étant déjà approuvé en Chine pour plusieurs indications auto-immunes.
Vor Bio (Nasdaq: VOR) hat Sandy Mahatme zum Chief Financial Officer und Chief Business Officer ernannt, wirksam ab dem 9. Juli 2025. Mahatme bringt über 30 Jahre Führungserfahrung in der biopharmazeutischen Industrie mit und war zuletzt Präsident, COO und CFO bei National Resilience, wo er über 2,5 Milliarden US-Dollar Kapital einwarb.
In seiner vorherigen Position bei Sarepta Therapeutics leitete Mahatme Kapitalbeschaffungsmaßnahmen von über 3,5 Milliarden US-Dollar und erweiterte die Produktpipeline des Unternehmens durch strategische Initiativen. Die Ernennung erfolgt, während Vor Bio die globale Phase-3-Entwicklung von Telitacicept bei generalisierter Myasthenia gravis vorantreibt; das Medikament ist bereits in China für mehrere Autoimmunerkrankungen zugelassen.
- None.
- Significant leadership transition during crucial Phase 3 development period
- Company will need substantial capital for global Phase 3 development and commercialization efforts
- Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company’s transformation and growth in autoimmune disease
CAMBRIDGE, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Sandy Mahatme as Chief Financial Officer and Chief Business Officer, effective July 9, 2025.
Mr. Mahatme joins Vor Bio with more than 30 years of executive leadership experience in the biopharmaceutical industry, with a strong track record in capital markets, business development, global operations, and shareholder value creation. He most recently served as President, Chief Operating Officer, and Chief Financial Officer of National Resilience, Inc., a biomanufacturing company he co-founded in 2020. During his tenure, he raised over
“We are thrilled to welcome Sandy to Vor Bio at such a pivotal time in the company’s evolution,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. “His financial acumen, operational discipline, and significant experience navigating strategic growth in both private and public biotech settings will be instrumental as we advance telitacicept through global Phase 3 development and pursue our broader mission to improve the lives of patients with autoimmune diseases.”
Prior to Resilience, Mr. Mahatme served as Executive Vice President, Chief Financial Officer and Chief Business Officer of Sarepta Therapeutics, where he led capital formation efforts exceeding
Mr. Mahatme currently serves on the boards of CRISPR Therapeutics and Idorsia Pharmaceuticals. He holds Master of Laws degrees from Cornell Law School and New York University School of Law and is a member of the New York Bar.
“Vor Bio is well positioned for success—a late-stage clinical asset already approved in China for multiple autoimmune indications and in Phase 3 global development for generalized myasthenia gravis outside of China, an experienced leadership team, and a top-tier investor base,” said Mr. Mahatme. “I’m excited to join this next chapter and help shape a company with the potential to change the treatment landscape for patients with autoimmune conditions.”
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding Vor Bio’s development plans for telitacicept, its ability to change the treatment landscape for patients with autoimmune conditions and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Inducement Plan Award
On July 9, 2025, the Board of Directors granted Mr. Mahatme 13,882,750 restricted stock units (“RSUs”) in connection with the commencement of his employment. The foregoing RSU award was granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”). The RSU will vest over a four-year period, with
Media & Investor Contacts:
Sarah Spencer
+1 857-242-6076
investors@vorbio.com
Carl Mauch
investors@vorbio.com
FAQ
Who is the new CFO and CBO of Vor Bio (Nasdaq: VOR)?
What is Sandy Mahatme's track record in capital raising?
What is the current status of Vor Bio's lead drug candidate?
What experience does Sandy Mahatme bring to Vor Bio?
What are Vor Bio's current development priorities?
